Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

527
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
527
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.0K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.0K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.1K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.1K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

856
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
856
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

517
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
517
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.2K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging trends in early-onset gastrointestinal cancers - a comparative review with late-onset cancers.

Expert review of anticancer therapy·2026
Same author

Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy.

Gut microbes·2026
Same author

Safety and effectiveness of the Colovac anastomosis protection device compared with diverting ileostomy after low anterior resection: protocol for an international, multicentre, prospective, non-randomised comparative study (SAFE-3).

BMJ open gastroenterology·2026
Same author

Surgical and clinical predictors of successful Hartmann reversal procedure after perforated diverticulitis.

Surgical endoscopy·2026
Same author

Subclinical anxiety and depression and postoperative complications after major colorectal surgery: A 2-center study.

Surgery·2026
Same author

Intestinal ultrasound to detect postoperative recurrence in patients with Crohn's disease: an international, multidisciplinary, RAND/UCLA appropriateness method study.

The lancet. Gastroenterology & hepatology·2026

Related Experiment Video

Updated: Feb 7, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.5K

Surgery in ulcerative colitis: When? How?

Gaetano Gallo1, Paulo Gustavo Kotze2, Antonino Spinelli3

  • 1Department of Medical and Surgical Sciences, O.U. of General Surgery, University of Catanzaro, Catanzaro, Italy; Department of Colorectal Surgery, S. Rita Clinic, Vercelli, Italy.

Best Practice & Research. Clinical Gastroenterology
|August 1, 2018
PubMed
Summary
This summary is machine-generated.

Ulcerative Colitis (UC) is a chronic inflammatory bowel disease. Management requires a multidisciplinary approach to optimize colectomy timing and procedures for patients with severe disease or cancer risk.

Keywords:
Inflammatory bowel diseaseMedicationsMultidisciplinary managementSurgeryTimingUlcerative colitis

More Related Videos

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K
Mouse Model of Pressure Ulcers After Spinal Cord Injury
06:51

Mouse Model of Pressure Ulcers After Spinal Cord Injury

Published on: March 9, 2019

10.1K

Related Experiment Videos

Last Updated: Feb 7, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.5K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K
Mouse Model of Pressure Ulcers After Spinal Cord Injury
06:51

Mouse Model of Pressure Ulcers After Spinal Cord Injury

Published on: March 9, 2019

10.1K

Area of Science:

  • Gastroenterology
  • Inflammatory Bowel Disease Research
  • Colorectal Cancer Etiology

Background:

  • Ulcerative Colitis (UC) is a chronic inflammatory bowel disorder with unknown etiology, likely involving genetic and environmental factors.
  • UC presents with bloody diarrhea and urgency, with disease extent predicting colectomy needs and potential complications like colorectal cancer (CRC).
  • UC-related CRC often arises from an inflammation-driven pathway, necessitating long-term endoscopic surveillance.

Purpose of the Study:

  • To review the current understanding of Ulcerative Colitis (UC) management.
  • To highlight the challenges in treating severe UC and preventing colectomy.
  • To emphasize the importance of a multidisciplinary approach in UC patient care.

Main Methods:

  • Review of existing literature on Ulcerative Colitis (UC) pathophysiology, clinical course, and treatment strategies.
  • Analysis of colectomy rates and salvage therapies including infliximab.
  • Discussion of surgical management settings (urgent, emergent, elective) and surveillance for UC-related colorectal cancer.

Main Results:

  • The anatomical extent of UC significantly impacts disease course and colectomy prediction.
  • Standard step-up therapy fails in one-third of patients, with salvage agents like infliximab showing limited long-term impact on colectomy rates.
  • Despite advancements, colectomy rates remain stable, and surgical management of UC presents ongoing challenges.

Conclusions:

  • A multidisciplinary approach is crucial for individualized UC management, optimizing treatment timing and surgical procedures.
  • Long-term surveillance is recommended for UC patients due to increased colorectal cancer risk.
  • Further research is needed to improve long-term outcomes and reduce colectomy rates in Ulcerative Colitis.